Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

UK Prime Minister Briefed on Israel-UK Collaborative Stem Cell Research

During a recent visit to Israel, British Prime Minister David Cameron, accompanied by Israel’s President, Shimon Peres, viewed an exhibition showcasing collaborative stem-cell research between the UK and the Hadassah Medical Organization.

Among the researchers who briefed the two leaders about her work was Dr. Sharona Even-Ramof Hadassah’s Goldyne Savad Institute of Gene Therapy, who discussed the use of regenerative cell therapy for Parkinson’s disease. In this particular joint project, embryonic stem cells are developed into nerve cells, which degenerate in Parkinson’s. Dr. Even-Ram is working on the project withProf. Kevin Shakesheffof the University of Nottingham.

Scientists from the two countries have been working together for the past two years on stem cell projects under a program directed by BIRAX, the British Israel Research and Academic Exchange Partnership Regenerative Medicine Initiative.BIRAX is a £10-million initiative of the British Embassy in Israel and the British Council, in collaboration with the Pears Foundation and the United Jewish Israel Appeal. It supports research that employs stem cell therapies to treat diseases such as Parkinson’s, Alzheimer’s, and diabetes. According to the British Council, over four million pounds has been committed to seven projects, “bringing together scientists in Britain and Israel to tackle some of the world’s most challenging health problems.”

The Institute of General Medicine comprises thirteen departments and nine Centers of Excellence. Each a leader in its field, the Centers include the Unit for the Early Detection of Colorectal Cancer, Center for Aging Research, National Center for Down Syndrome, and National SLE (LUPUS) Center. Its stellar Intensive Care Unit is world renowned.

DONATE

Join

Advocate

Lead

LEARN MORE

View all of our Impact Areas

Prime Minister Cameron recently launched a call for new UK-Israel collaborative research into Alzheimer’s, type 1 diabetes, heart disease, and Parkinson’s. Proposals are due in May.

Read more in Times of Israel

Date: 3/20/2014

Hadassah Stem Cell Expert Speaks at TEDx Conference in Jaffa

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Hadassah Physicians Receive Prestigious Grants and Awards

New Research at Hadassah: Computational Tools Unravel the Mystery of Transient Amnesia

From Life-Threatening Brain Bleed to Birth of a Daughter

Cookbook Author, Rabbi Marks, Spends Last Days at Hadassah's Hospice

Hadassah’s Revolutionary Tipat Halav Clinics of 1920s Featured in Jerusalem Old City Museum

Victims of Terror Share Their Stories of Anguish and Appreciation with Hadassah President

Hadassah’s Advanced Gene Sequencing Changes the Life of a Family from Uzbekistan

IDF Medic Heroically Battles Terrorist, Both Treated at Hadassah

Orthopedic Trauma Turns Tragedy into Innovation at Hadassah

On the Cutting-Edge of Melanoma Treatment: Hadassah’s Protocols and Research

Saving a Newborn from a Life Without Sight

Terrorist and Victim Sent to Hadassah's Hospitals After Third Attack in Two Weeks

Three Sent to Hadassah After Second Jerusalem Terror Attack of the Week

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

“We Don’t Say ‘No’,” Hadassah Neurosurgeon Explains in Operating on 82-Year-Old Patient

Cutting-Edge Medicine and Research; a Role Model for Peace: A Briefing from the Hospital's Director General

4 Ways Hadassah Hospital is Preparing for Ebola—Just in Case

Hailing from 17 Countries: the 39th Graduation Class of Hadassah’s International Master of Public Health Program



More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America